TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05189067

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: i.v. 80mg/m\^2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: i.v. loading dose of 8 mg/kg, followed by 6mg/kg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trastuzumab
Description: i.v. loading dose of 8 mg/kg, followed by 6mg/kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: i.v. 100mg/m2
Study: NCT06124482

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Total Knee arthroplasty
Description: The FHK-CK prosthesis (non CE-Marked, class III) is to be implanted with the use of FHK-CK instruments. The surgery has to be performed in accordance with the practice/guidelines, FHK-CK Instruction For Use (IFU) and surgical techniques documents.
Study: NCT04759742

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ropivacaine
Description: According to previous clinical experience, 0.5% ropivacaine was given in the subarachnoid cavity, and the initial dose was set at 2.5 mL (12.5mg). Dixon's up-and down method was adopted to adjust or down-adjust the dose of ropivacaine in the next patient according to the experimental results of the previous patient, and the adjusted dose was 0.1 mL (0.5mg).
Study: NCT01003704

Intervention type: PROCEDURE
Intervention: Lower extremity amputation

Intervention type: PROCEDURE
Intervention: Lower extremity amputation

Intervention type: PROCEDURE
Intervention: Lower extremity amputation
Study: NCT04736017

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: TSB Axo
Description: The TSB Axo is a wearable biosignal recording device combined with an auditory stimulation. The device consists of pre-gelled biosignal electrodes, headphones integrated in a headband, and a biosignal processing module.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TSB Axo
Description: The TSB Axo is a wearable biosignal recording device combined with an auditory stimulation. The device consists of pre-gelled biosignal electrodes, headphones integrated in a headband, and a biosignal processing module.
Study: NCT06149052

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: SMART TRAINING
Description: Patients in Group A received SMART training intervention. For sensory stimulation planter massage was given, and it was applied to entire planter surface. Grade III anterior to posterior talocrural joint mobilization was given (26). For balance, single and double leg stance was performed. For functional training, lateral hops and SEBT was performed. And at the end, for resistance training, theraband was used with normal ankle joint movement. There is a progress in focus between the five domains over the 3weeks, as described below: The domains S and M are present across the whole intervention. In week 1, the main focus is on the A domain, in week 2 on the R domain, and in week 3 on the T domain. During the 3-week intervention period, 3 training sessions was held per week each lasting approximately 45 - 60 min, including 10 min warm up

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: FIRE training
Description: Patients in Group B was received foot intensive rehabilitation (FIRE).The FIRE intervention was include the progressive balance training, ankle and hip strengthening, range of motion exercises and foot massage. Plantar massage consisted of two, 1-min plantar massages with a 1-min rest between sets. Four previously established exercises were targeted the IFMs including the short-foot, toe-spread-out, hallux extension, and lesser-toe extension
Study: NCT06450574

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine (Xeloda)
Description: Capecitabine 825 mg/m2 every 12 hours orally on days of radiotherapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 50.4 Gy
Description: Radiotherapy was administered in daily fractions of 1.8 Gy 5 days a week according to standard schema. The total dose is 45 Gy plus a boost of 5.4 Gy to the tumor area

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transanal Endoscopic Microsurgery (TEM)
Description: 10 weeks after Chemoradiotherapy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transanal Endoscopic Microsurgery
Description: Standard surgical treatment of T1, N0, M0 rectal cancer. Early after diagnosis
Study: NCT04932382

Intervention type: DRUG
Group type: OTHER
Intervention: Misoprostol
Description: will be used 3 h before IUD insertion

Intervention type: DEVICE
Group type: OTHER
Intervention: IUD
Description: a copper T380A IUD

Intervention type: DEVICE
Group type: OTHER
Intervention: IUD
Description: a copper T380A IUD
Study: NCT06310603

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low-Processed Food Diet
Description: Participants that receive intervention will be instructed to eat a diet rich in unprocessed/minimally-processed foods, as described by the NOVA food classification system
Study: NCT04761055

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Clinical Breast exam (CBE)
Description: The standard CBE will be performed by a nurse practitioner (NP) who will record any positive CBE finding.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: iBreastExam device
Description: The iBE is an FDA 510(k) cleared portable device which utilizes an array of dynamic capacitive pressure sensors to perform electronic palpation for breast abnormalities. The iBE exam will be administered by a mammogram technologist, blinded to CBE results.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: mammogram
Description: All patients will have routine standard mammographic views performed. Patients with positive iBE and/or CBE findings will have additional mammographic and/or ultrasound imaging to determine if a correlating breast lesion is present using the same standard of care algorithm as is used currently for positive CBE findings.
Study: NCT05670236

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine Hydrochloride
Description: 10 mL of 1% lidocaine hydrochloride for each intraarticular knee injection
Study: NCT05666544

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Web-based patient decision aid
Description: After the clinic, use web-based patient decision aid of renal replacement therapy to conduct education.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Written health education leaflets
Description: After the clinic, use a written health education leaflet on renal replacement therapy to conduct education.
Study: NCT05445856

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methadone
Description: Methadone is administered as a single intravenous dose after induction of anesthesia and prior to initiation of surgery

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Description: Fentanyl is administered as a single intravenous dose after induction of anesthesia and prior to initiation of surgery
Study: NCT06184490

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Prone position with thoraco-abdominal cushion
Description: Prone position with cushions positioned laterally on the chest, abdomen, and pelvis
Study: NCT05001295

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Physical Activity
Description: Following the guidelines of NICE, the program to be followed by the IG is designed so that the intervention lasts 5 weeks, divided into 4 levels of progressive intensity, in which sessions of 30 to 45 minutes of aerobic exercise will be carried out 2 days a week. week.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Physical Activity
Description: Following the guidelines of NICE, the program to be followed by the IG is designed so that the intervention lasts 5 weeks, divided into 4 levels of progressive intensity, in which sessions of 30 to 45 minutes of aerobic exercise will be carried out 2 days a week. week.
Study: NCT05623670

Intervention type: PROCEDURE
Intervention: minimally invasive cardiac surgery using a VJI cannula.
Description: Observation of postinterventional internal jugular vein thrombus after minimally invasive cardiac surgery using VJI cannulation to achieve complete CPB.
Study: NCT04988971

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: a compound glutamine capsule
Description: A compound glutamine capsule was taken orally from the first day of chemotherapy, orally 3 times a day after meals, 3 tablets each time, the course of treatment is 3 weeks.
Study: NCT04765813

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral treatment to quit smoking along with an App with active therapeutic components
Description: Cognitive-behavioral smoking cessation treatment components will be: treatment contract, self-report and graphic representation of cigarette consumption, information about tobacco, stimulus control, activities for the avoidance of withdrawal syndrome, physiological feedback (CO in expired air) on cigarette consumption, nicotine fading (change of cigarette brands each week progressively decreasing the intake of nicotine and tar), and relapse-prevention strategies (assertion training, problem-solving training, change tobacco-related misconceptions, management of anxiety and anger, exercise, weight control, self-reinforcing, and changing irrational beliefs).~Participants will use a smartphone App with therapeutic components during the intervention (8 weeks) and follow-up period (time frame: one year).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive-behavioral treatment to quit smoking along with a control App
Description: Cognitive-behavioral smoking cessation treatment components will be: treatment contract, self-report and graphic representation of cigarette consumption, information about tobacco, stimulus control, activities for the avoidance of withdrawal syndrome, physiological feedback (CO in expired air) on cigarette consumption, nicotine fading (change of cigarette brands each week progressively decreasing the intake of nicotine and tar), and relapse-prevention strategies (assertion training, problem-solving training, change tobacco-related misconceptions, management of anxiety and anger, exercise, weight control, self-reinforcing, and changing irrational beliefs).~Participants will use a control smartphone App (only to access session materials) during the intervention period (8 weeks).
Study: NCT06353919

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Yoga Nidra
Description: Recordings were created to allow participants access to a variety of Yoga Nidra practices. Participants will be instructed to complete a 30-minute Yoga Nidra 3-5 times per week, at any time of day or night (including before bed and/or during bouts of sleeplessness). This duration and frequency is informed by previous studies.~Related to intentionally decreasing BZRA use, the recording requests each practitioner to set a resolve/personal goal at the start of each practice, and they are asked to repeat it again at the end. In our study, participants will be asked to develop a short and simple resolve in their own words, related to reducing BZRA use, improving sleep and decreasing anxiety, and they will be asked to recite it at each practice.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sleep Hygiene, Anxiety, and Benzodiazepine Receptor Agonist Education
Description: Participants will be instructed to access excerpts from standardized and trusted materials through our online platform for 30 minutes, 3-5 times per week.
Study: NCT04988971

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: a compound glutamine capsule simulated placebo
Description: a compound glutamine capsule simulated placebo was taken orally from the first day of chemotherapy, orally 3 times a day after meals, 3 tablets each time, the course of treatment is 3 weeks.
Study: NCT06438419

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electrophysiological recordings
Description: Electrophysiological recordings will be made during a motor task in four different conditions:~1. without pharmacological treatment and without stimulation (Off condition),~2. without pharmacological treatment and during stimulation (DBS condition),~3. during pharmacological treatment and without stimulation (DOPA condition),~4. during pharmacological treatment and stimulation (DOPA+DBS condition).
Study: NCT06108089

Intervention type: DIAGNOSTIC_TEST
Intervention: [18F]MISO-PET/CT
Description: 18F\]MISO-PET/CT will be acquired in each patient as the standard of references of tumor hypoxia.

Intervention type: DIAGNOSTIC_TEST
Intervention: [18F]MISO-PET/CT
Description: 18F\]MISO-PET/CT will be acquired in each patient as the standard of references of tumor hypoxia.
Study: NCT05978713

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tirzepatide
Description: Administered SC
Study: NCT06523023

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: An integrated online program
Description: Our integrated online program combines validated psychoeducational materials on dissociation with components of strucutred writing therapy.
Study: NCT05619913

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eribulin Mesylate
Description: Eribulin mesilate is a first-in-class halichondrin B-based, microtubule dynamics inhibitor7. It inhibits the growth phase of microtubules without affecting the shortening phase and sequesters tubulin into non-productive aggregates.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eribulin Mesylate
Description: Eribulin mesilate is a first-in-class halichondrin B-based, microtubule dynamics inhibitor7. It inhibits the growth phase of microtubules without affecting the shortening phase and sequesters tubulin into non-productive aggregates.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab is a potent humanized immunoglobulin G4 (IgG4) monoclonal antibody (mAb) with high specificity of binding to the programmed cell death 1 (PD 1) receptor, thus inhibiting its interaction with programmed cell death ligand 1 (PD-L1) and programmed cell death ligand 2 (PD-L2).
Study: NCT06523023

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: An integrated online program
Description: Our integrated online program combines validated psychoeducational materials on dissociation with components of strucutred writing therapy.
Study: NCT05404880

Intervention type: DEVICE
Intervention: EDWARDS INSPIRIS RESILIA Aortic Valve
Description: Surgical replacement of the aortic valve with the INSPIRIS RESILIA Aortic Valve.
Study: NCT04842617

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR6390
Description: SHR6390 combined with endocrine therapy

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo combined with endocrine therapy
Study: NCT05774795

Intervention type: PROCEDURE
Intervention: Mitral valve surgery
Description: Mitral valve repair or replacement to treat mitral regurgitation

Intervention type: PROCEDURE
Intervention: Mitral valve surgery
Description: Mitral valve repair or replacement to treat mitral regurgitation

Intervention type: PROCEDURE
Intervention: Aortic valve surgery
Description: Aortic valve replacement to treat aortic regurgitation
Study: NCT05979935

Intervention type: DIAGNOSTIC_TEST
Intervention: tongue diagnosis
Description: The tongue image of participants will be collected via camera and professional tongue diagnosis report will be provided to pariticipants.

Intervention type: DIAGNOSTIC_TEST
Intervention: tongue diagnosis
Description: The tongue image of participants will be collected via camera and professional tongue diagnosis report will be provided to pariticipants.
Study: NCT05808530

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Stimulation Therapy
Description: CST involves the use of standard tasks that focus on cognitive functions, designed to meet varying levels of difficulty in accordance with the individual's ability and rehabilitation. A detailed guide for CST is available for a range of health and care professionals, including care workers, occupational therapists, psychologists, and nurses (https://www.ucl.ac.uk/international-cognitive-stimulation-therapy/) publications/cst-manuals). The CST application consists of 14 sessions of 45-50 minutes, 2 days a week.~Intervention Group Week 1=Getting acquainted and applying pre-tests Week 2=Physical games and Sounds Week 3=Childhood and Food Week 4=Current events and Faces / Scenes Week 5=Word association and Creativity Week 6=Categorizing Objects and Orientation Week 7= Money usage and Games Week 8=Word Games and Team Competition Week 9=Closing and post-test application
Study: NCT05128630

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Patients will receive 1500 mg durvalumab via IV infusion q3w concomitant with chemotherapy (Cisplatin/carboplatin plus etoposide) for up to a maximum of 3 cycles, then via IV infusion at the same interval during sequential radiotherapy and then every 4 weeks for up to a maximum of 12 months or until confirmed disease progression, unless there is unacceptable toxicity, withdrawal of consent, or another discontinuation criterion is met.
Study: NCT05209126

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Beetroot juice
Description: Acute effects of beetroot juice ingestion on neuromuscular performance in female rugby players

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Beetroot juice
Description: Acute effects of beetroot juice ingestion on neuromuscular performance in female rugby players
Study: NCT05099614

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Naloxone hydrochloride injection solution, SmartDose wearable auto injector and mobile respiratory sensing system
Description: 1.2 mg of naloxone hydrochloride is administered to healthy adults using the SmartDose wearable auto injector and the mobile respiratory sensing system.
Study: NCT05511207

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RECOM - hBCI training
Description: The RECOM device is a h-BCI system that controls FES of upper limb muscles: the patient is asked to attempt simple upper limb movements (eg extension of fingers); the device recognizes (in correct trials) close-to-normal EEG-EMG activation and initiates FES of extensor muscles in the forearm. RECOM training consists in a set of trial repetition for a total duration per session of approximately 20-30 minutes (excluding set up time and calibration). FES parameters will be set specifically for each patients according to standard guidelines to achieve full movement and so as to avoid any kind of discomfort for the patients. The intervention regimen will be 2-3 times per week for 4 consecutive weeks.
Study: NCT05023941

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetazolamide
Description: Start orally take acetazolamide 125mg twice daily, 2 days before entering the hypoxic chamber. Subjects will enter the hypoxic room at 9am on the third day. At that time, the subject should have taken the drug 5 times.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetazolamide
Description: Start orally take acetazolamide 125mg twice daily, 2 days before entering the hypoxic chamber. Subjects will enter the hypoxic room at 9am on the third day. At that time, the subject should have taken the drug 5 times.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Doctormate® (twice daily for 6 days)
Description: Start RIPC training twice daily, 6 days before entering the hypoxic chamber. RIPC will be induced by Renqiao Remote Ischemic Conditioning Device (Doctormate®). Each training will be comprised of 5 cycles of bilateral upper limb ischemia and reperfusion, which will be induced by 2 cuffs placed around the upper arms respectively and inflated to 200mmHg for 5 minutes followed by 5 minutes of reperfusion by cuff deflation. Subjects will enter the hypoxic room at 9am on the seventh day. At that time, the subject should have finished 13 times of RIPC training.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Doctormate® (forth daily for 3 days)
Description: Start RIPC training forth daily, 3 days before entering the hypoxic chamber. RIPC will be induced by Renqiao Remote Ischemic Conditioning Device (Doctormate®). Each training will be comprised of 5 cycles of bilateral upper limb ischemia and reperfusion, which will be induced by 2 cuffs placed around the upper arms respectively and inflated to 200mmHg for 5 minutes followed by 5 minutes of reperfusion by cuff deflation. Subjects will enter the hypoxic room at 9am on the forth day. At that time, the subject should have finished 13 times of RIPC training.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Doctormate® (forth daily for 3 days)
Description: Start RIPC training forth daily, 3 days before entering the hypoxic chamber. RIPC will be induced by Renqiao Remote Ischemic Conditioning Device (Doctormate®). Each training will be comprised of 5 cycles of bilateral upper limb ischemia and reperfusion, which will be induced by 2 cuffs placed around the upper arms respectively and inflated to 200mmHg for 5 minutes followed by 5 minutes of reperfusion by cuff deflation. Subjects will enter the hypoxic room at 9am on the forth day. At that time, the subject should have finished 13 times of RIPC training.
Study: NCT01561092

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Escitalopram
Description: 5 or 10 mg escitalopram tablets administered orally once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablets
Study: NCT06172218

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Flo
Description: sterile, micronized human amniotic membrane product derived from placenta and umbilical cord

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Saline
Description: sterile, preservative free 0.9% NaCl
Study: NCT05511207

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: CTRL - upper limb training with FES
Description: An expert physiotherapist will define a set of active exercises focused on upper limb function; the exercises will be combined with FES of forearm muscles. FES parameters will be set specifically for each patients according to standard guidelines to achieve the full required movement and so as to avoid any kind of discomfort for the patients. Session duration will be approximately 20-30 minutes (excluding FES calibration time). The intervention regimen will be 2-3 times per week for 4 consecutive weeks.
Study: NCT06172218

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: sterile, preservative free 0.9% NaCl
Study: NCT05170308

Intervention type: DEVICE
Group type: OTHER
Intervention: CO2 fractional laser
Description: The study subjects' body will be divided into two equal halves along sagittal midline section with one side receiving treatment with fractional CO2 laser (experimental) to treat dyspigmentation in lichen planus pigmentosus
Study: NCT05400070

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neoadjuvant therapy 1
Description: Dosing regimen Sintilimab (200mg fixed dose) iv, d1, q3w + anlotinib 10mg, po, qd1-14, q3w, was evaluated after 3 cycles of chemotherapy and stopped for 3 weeks (21 days) after surgery for 4-6 weeks (21-42 days) after the last dose.
Study: NCT04582916

Intervention type: DRUG
Group type: OTHER
Intervention: 11C-MCI
Description: Injected IV followed by PET scanning

Intervention type: DRUG
Group type: OTHER
Intervention: 11CPS13
Description: Injected IV followed by PET scanning